Abstract

Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but introduce non-trivial drug design parameters that must be considered as part of target selection and lead identification. Applied BioMath Assess with the Avidity Model Pack supports early feasibility assessment for bispecific modalities. This poster demonstrates how to use Applied BioMath Assess to identify the level of avidity required for a drug to have a favorable efficacy and therapeutic index. It also illustrates how drug design decisions can benefit from modeling and simulation due to non-trivial impacts on drug behavior.

This work was initially presented by Applied BioMath. Applied BioMath was acquired by Certara in December 2023.